- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ATL revenues up, net loss drops
Ultrasound vendor Advanced TechnologyLaboratories reported higher revenues for its third quarter (end-September),but ended the quarter with a net loss due to higher operatingexpenses associated with product introductions such as the company'snew HDI 3000
Ultrasound vendor Advanced TechnologyLaboratories reported higher revenues for its third quarter (end-September),but ended the quarter with a net loss due to higher operatingexpenses associated with product introductions such as the company'snew HDI 3000 scanner.
ATL, of Bothell, WA, recorded third-quarter revenues of $87.3million, up 11% over the $78.6 million in the same period lastyear. The company had a net loss of $4.8 million in the quarterversus a net loss of $8.5 million in the third quarter of 1993.The 1993 results included a $4.3 million restructuring charge(SCAN 9/8/93).
The company's investment in new product development was reflectedin a 19% increase in R&D expenses, to $15.1 million. Salesand administrative costs rose 8% to $28.5 million due to the initialcosts of launching HDI 3000, as well as international expansionand the introduction of Interspec's Apogee products, which ATLacquired earlier this year (SCAN 2/16/94). Those products arebeginning to contribute to growth in ATL's international business.
For the first nine months of 1994, ATL had revenues of $261.5million and a net loss of $14.4 million, which includes one-timeexpenses of $5.4 million for the Interspec acquisition. In thesame period last year, ATL's revenues were $262 million and itsnet loss was $7.7 million.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
